Synthetic liver X receptor agonist T0901317 inhibits semicarbazide-sensitive amine oxidase gene expression and activity in apolipoprotein E knockout mice
Xiaoyan Dai
Institute of Cardiovascular Research, Key Laboratory for Atherosclerology of Hunan Province, University of South China, Hengyang 421001, China
Search for more papers by this authorXiang Ou
Institute of Cardiovascular Research, Key Laboratory for Atherosclerology of Hunan Province, University of South China, Hengyang 421001, China
Search for more papers by this authorXinrui Hao
Institute of Cardiovascular Research, Key Laboratory for Atherosclerology of Hunan Province, University of South China, Hengyang 421001, China
Search for more papers by this authorDongli Cao
Institute of Cardiovascular Research, Key Laboratory for Atherosclerology of Hunan Province, University of South China, Hengyang 421001, China
Search for more papers by this authorYaling Tang
Institute of Cardiovascular Research, Key Laboratory for Atherosclerology of Hunan Province, University of South China, Hengyang 421001, China
Search for more papers by this authorYanwei Hu
Institute of Cardiovascular Research, Key Laboratory for Atherosclerology of Hunan Province, University of South China, Hengyang 421001, China
Search for more papers by this authorXiaoxu Li
Institute of Cardiovascular Research, Key Laboratory for Atherosclerology of Hunan Province, University of South China, Hengyang 421001, China
Search for more papers by this authorCorresponding Author
Chaoke Tang
Institute of Cardiovascular Research, Key Laboratory for Atherosclerology of Hunan Province, University of South China, Hengyang 421001, China
*Corresponding author: Tel, 86-734-8281279; Fax, 86-734-8281288; E-mail, [email protected]Search for more papers by this authorXiaoyan Dai
Institute of Cardiovascular Research, Key Laboratory for Atherosclerology of Hunan Province, University of South China, Hengyang 421001, China
Search for more papers by this authorXiang Ou
Institute of Cardiovascular Research, Key Laboratory for Atherosclerology of Hunan Province, University of South China, Hengyang 421001, China
Search for more papers by this authorXinrui Hao
Institute of Cardiovascular Research, Key Laboratory for Atherosclerology of Hunan Province, University of South China, Hengyang 421001, China
Search for more papers by this authorDongli Cao
Institute of Cardiovascular Research, Key Laboratory for Atherosclerology of Hunan Province, University of South China, Hengyang 421001, China
Search for more papers by this authorYaling Tang
Institute of Cardiovascular Research, Key Laboratory for Atherosclerology of Hunan Province, University of South China, Hengyang 421001, China
Search for more papers by this authorYanwei Hu
Institute of Cardiovascular Research, Key Laboratory for Atherosclerology of Hunan Province, University of South China, Hengyang 421001, China
Search for more papers by this authorXiaoxu Li
Institute of Cardiovascular Research, Key Laboratory for Atherosclerology of Hunan Province, University of South China, Hengyang 421001, China
Search for more papers by this authorCorresponding Author
Chaoke Tang
Institute of Cardiovascular Research, Key Laboratory for Atherosclerology of Hunan Province, University of South China, Hengyang 421001, China
*Corresponding author: Tel, 86-734-8281279; Fax, 86-734-8281288; E-mail, [email protected]Search for more papers by this authorThis work was supported by the grants from the National Natural Science Foundation of China (30470720), Post-doctoral Sciences Foundation of China (2005037157), and Natural Science Foundation of Hunan Province (06jj5058)
Abstract
Semicarbazide-sensitive amine oxidase (SSAO) catalyzes oxidative deamination of primary aromatic and aliphatic amines. Increased SSAO activity has been found in atherosclerosis and diabetes mellitus. We hypothesize that the anti-atherogenic effect of liver X receptors (LXRs) might be related to the inhibition of SSAO gene expression and its activity. In this study, we investigated the effect of LXRagonist T0901317 on SSAO gene expression and its activity in apolipoprotein E knockout (apoE−/−) mice. Male apoE−/− mice (8 weeks old) were randomly divided into four groups: basal control group; vehicle group; prevention group; and treatment group. SSAO gene expression was analyzed by real-time quantitative polymerase chain reaction and its activity was determined. The activity of superoxide dismutase and content of malondialdehyde in the aorta and liver were also determined. In T0901317-treated mice, SSAO gene expression was significantly decreased in the aorta, liver, small intestine, and brain. SSAO activities in serum and in these tissues were also inhibited. The amount of superoxide dismutase in the aorta and liver of the prevention group and treatment group was significantly higher compared with the vehicle group (P < 0.05). Malondialdehyde in the tissues of these two groups was significantly lower compared with the vehicle group (P < 0.05). Our results showed that T0901317 inhibits SSAO gene expression and its activity in atherogenic apoE−/− mice. The atheroprotective effect of LXR agonist T0901317 is related to the inhibition of SSAO gene expression and its activity.
References
- 1 Yu PH, Lu LX, Fan H, Kazachkov M, Jiang ZJ, Jalkanen S, Stolen C. Involvement of semicarbazide-sensitive amine oxidase-mediated deamination in lipopolysaccharide-induced pulmonary inflammation. Am J Pathol 2006, 168: 718–726.
- 2 Bour S, Daviaud D, Gres S, Lefort C, Prevot D, Zorzano A, Wabitsch M et al. Adipogenesis-related increase of semicarbazide-sensitive amine oxidase and monoamine oxidase in human adipocytes. Biochimie 2007, 89: 916–925.
- 3 Wanecq E, Bour S, Verwaerde P, Smih F, Valet P, Carpene C. Increased monoamine oxidase and semicarbazide-sensitive amine oxidase activities in white adipose tissue of obese dogs fed a high-fat diet. J Physiol Biochem 2006, 62: 113–123.
- 4 Yu PH. Oxidative deamination of aliphatic amines by rat aorta semicarbazide-sensitive amine oxidase. J Pharm Pharmacol 1990, 42: 882–884.
- 5 Boor PJ, Trent MB, Lyles GA, Tao M, Ansari GA. Methylamine metabolism to formaldehyde by vascular semicarbazide-sensitive amine oxidase. Toxicology 1992, 73: 251–258.
- 6 Porter DJ. Binding of 2-acetylpyridine-5-[(2-chloroanilino) thiocarbonyl] thiocarbonohydrazone (BW348U87) to human serum albumin. Biochem Pharmacol 1992, 44: 1417–1429.
- 7 Lyles GA. Substrate-specificity of mammalian tissue-bound semicarbazide-sensitive amine oxidase. Prog Brain Res 1995, 106: 293–303.
- 8 Salmi M, Stolen C, Jousilahti P, Yegutkin GG, Tapanainen P, Janatuinen T, Knip M et al. Insulin-regulated increase of soluble vascular adhesion protein-l in diabetes. Am J Pathol 2002, 161: 2255–2262.
- 9 Boomsma F, Van Den Meiracker AH, Winkel S, Aanstoot HJ, Batstra MR, Man in't Veld AJ, Bruining GJ. Circulating semicarbazide-sensitive amine oxidase is raised both in type I (insulin-dependent), in type II (non-insulin-dependent) diabetes mellitus and even in childhood type I diabetes at first clinical diagnosis. Diabetologia 1999, 42: 233–237.
- 10 Karadi I, Meszaros Z, Csanyi A, Szombathy T, Hosszufalusi N, Romics L, Magyar K. Serum semicarbazide-sensitive amine oxidase (SSAO) activity is an independent marker of carotid atherosclerosis. Clin Chim Acta 2002, 323: 139–146.
- 11 Meszaros Z, Karadi I, Csanyi A, Szombathy T, Romics L, Magyar K. Determination of human serum semicarbazide-sensitive amine oxidase activity: a possible clinical marker of atherosclerosis. Eur J Drug Metab Pharmacokinet 1999, 24: 299–302.
- 12 Boomsma F, Van Veldhuisen DJ, De Kam PJ, Man in't Veld AJ, Mosterd A, Lie KI, Schalekamp MA. Plasma semicarbazide-sensitive amine oxidase is elevated in patients with congestive heart failure. Cardiovasc Res 1997, 33: 387–391.
- 13 Boomsma F, De Kam PJ, Tjeerdsma G, Van Den Meiracker AH, Van Veldhuisen DJ. Plasma semicarbazide-sensitive amine oxidase (SSAO) is an independent prognostic marker for mortality in chronic heart failure. Eur Heart J 2000, 21: 1859–1863.
- 14 Meszaros Z, Szombathy T, Raimondi L, Karadi I, Romics L, Magyar K. Elevated serum semicarbazide-sensitive amine oxidase activity in non-insulin-dependent diabetes mellitus. Correlation with body mass index and serum triglyceride. Metabolism 1999, 48: 113–117.
- 15 Kurkijärvi R, Yegutkin GG, Gunson BK, Jalkanen S, Salmi M, Adams DH. Circulating soluble vascular adhesion protein 1 accounts for the increased serum monoamine oxidase activity in chronic liver disease. Gastroenterology 2000, 119: 1096–1103.
- 16 Kurkijarvi R, Adams DH, Leino R, Mottonen T, Jalkanen S, Salmi M. Circulating form of human vascular adhesion protein-1 (VAP-1): increased serum levels in inflammatory liver diseases. J Immunol 1998, 161: 1549–1557.
- 17 Lehmann JM, Kliewer SA, Moore LB, Smith-Oliver TA, Oliver BB, Su JL, Sundseth SS et al. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J Biol Chem 1997, 272: 3137–3140.
- 18 Tangirala RK, Bischoff ED, Joseph SB, Wagner BL, Walczak R, Laffitte BA, Daige CL et al. Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proc Natl Acad Sci USA 2002, 99: 11896–11901.
- 19 Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med 2003, 9: 213–219.
- 20 Joseph SB, McKilligin E, Pei L, Watson MA, Collins AR, Laffitte BA, Chen M et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci USA 2002, 99: 7604–7609.
- 21 Terasaka N, Hiroshima A, Koieyama T, Ubukata N, Morikawa Y, Nakai D, Inaba T. T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice. FEBS Lett 2003, 536: 6–11.
- 22 Geyeregger R, Zeyda M, Stulnig TM. Liver X receptors in cardiovascular and metabolic disease. Cell Mol Life Sci 2006, 63: 524–539.
- 23 Kennedy MA, Venkateswaran A, Tarr PT, Xenarios I, Kudoh J, Shimizu N, Edwards PA. Characterization of the human ABCG1 gene: liver X receptor activates an internal promoter that produces a novel transcript encoding an alternative form of the protein. J Biol Chem 2001, 276: 39438–39447.
- 24 Sabol SL, Brewer HB Jr, Santamarina-Fojo S. The human ABCG1 gene: identification of LXR response elements that modulate expression in macrophages and liver. J Lipid Res 2005, 46: 2151–2167.
- 25 Tang CK, Yi GH, Yang JH, Liu LS, Wang Z, Ruan CG, Yang YZ. Oxidized LDL upregulated ATP binding cassette transporter A1 in THP-1 macrophages. Acta Pharmacol Sin 2004, 25: 581–586.
- 26 Tang CK, Tang GH, Yi GH, Wang Z, Liu LS, Wan S, Yuan ZH et al. Effect of apolipoprotein A-I on ATP binding cassette transporter A1 degradation and cholesterol efflux in THP-1 macrophage-derived foam cells. Acta Biochim Biophys Sin 2004, 36: 218–226.
- 27 Tang CK, Yang JH, Yi GH, Wang Z, Liu LS, Wan ZY, Yuan ZH et al. Effects of oleate on ATP binding cassette transporter A1 expression and cholesterol efflux in THP-1 macrophage-derived foam cells. Acta Biochim Biophys Sin 2003, 35: 1077–1082.
- 28 Castrillo A, Joseph SB, Vaidya SA, Haberland M, Fogelman AM, Cheng G, Tontonoz P. Crosstalk between LXR and toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. Mol Cell 2003, 12: 805–816.
- 29 Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H. Role of oxidative stress in atherosclerosis. Am J Cardiol 2003, 91: 7A–11A.
- 30 Somers MJ, Harrison DG. Reactive oxygen species and the control of vasomotor tone. Curr Hypertens Rep 1999, 1: 102–108.
- 31 Levonen AL, Patel RP, Brookes P, Go YM, Jo H, Parthasarathy S, Anderson PG et al. Mechanisms of cell signaling by nitric oxide and peroxynitrite: from mitochondria to MAP kinases. Antioxid Redox Signal 2001, 3: 215–229.
- 32 Gokturk C, Nordquist J, Sugimoto H, Forsberg-Nilsson K, Nilsson J, Oreland L. Semicarbazide-sensitive amine oxidase in transgenic mice with diabetes. Biochem Biophys Res Commun 2004, 325: 1013–1020.
- 33 Feng JL, Chen SN, Tang XS, Ding XF, Du ZY, Chen JS. Quantitative determination of cucumber mosaic virus genome RNAs in virions by real-time reverse transcription-polymerase chain reaction. Acta Biochim Biophys Sin 2006, 38: 669–676.
- 34 McCaman RE. Microdetermination of catechol-O-methyl transferase in brain. Life Sci 1965, 4: 2353–2359.
- 35 Lowry O, Rosebrough N, Farr A, Randall R. Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193: 265–275.
- 36 Dai K, Qi JY, Tian DY. Leptin administration exacerbates thioacetamide-induced liver fibrosis in mice. World J Gastroenterol 2005, 11: 4822–4826.
- 37 Claudel T, Leibowitz MD, Fiévet C, Tailleux A, Wagner B, Repa JJ, Torpier G et al. Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor. Proc Natl Acad Sci USA 2001, 98: 2610–2615.
- 38 Aiello RJ, Bourassa PA, Lindsey S, Weng W, Freeman A, Showell HJ. Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice. Arterioscler Thromb Vasc Biol 2002, 22: 443–449.
- 39 Marleau S, Harb D, Bujold K, Avallone R, Iken K, Wang Y, Demers A et al. EP 80317, a ligand of the CD36 scavenger receptor, protects apolipoprotein E-deficient mice from developing atherosclerotic lesions. FASEB J 2005, 19: 1869–1871.
- 40 Navab M, Berliner JA, Watson AD, Hama SY, Territo MC, Lusis AJ, Shih DM et al. The yin and yang of oxidation in the development of the fatty streak. Arterioscler Thromb Vasc Biol 1996, 16: 831–842.
- 41 Ross R. Atherosclerosis—an inflammatory disease. N Eng J Med 1999, 340: 115–126.
- 42 Ross R, Harker L. Hyperlipidemia and atherosclerosis. Science 1976, 193: 1094–1100.
- 43 Sanders M. Molecular and cellular concepts in atherosclerosis. Pharmacol Ther 1994, 61: 109–153.
- 44 Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 2005, 96: 1221–1232.
- 45 Chiang JY, Kimmel R, Stroup D. Regulation of cholesterol 7 alpha-hydroxylase gene (CYP7A1) transcription by the liver orphan receptor (LXRα). Gene 2001, 262: 257–265.
- 46 Repa JJ, Berge KE, Pomajzl C, Richardson JA, Hobbs H, Mangelsdorf DJ. Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. J Biol Chem 2002, 277: 18793–18800.
- 47 Castrillo A, Joseph SB, Marathe C, Mangelsdorf DJ, Tontonoz P. Liver X receptor-dependent repression of matrix metalloproteinase-9 expression in macrophages. J Biol Chem 2003, 278: 10443–10449.
- 48 Terasaka N, Hiroshima A, Ariga A, Honzumi S, Koieyama T, Inaba T, Fujiwara T. Liver X receptor agonists inhibit tissue factor expression in macrophages. FEBS J 2005, 272: 1546–1556.
- 49 Ogawa D, Stone JF, Takata Y, Blaschke F, Chu VH, Towler DA, Law RE et al. Liver X receptor agonists inhibit cytokine-induced osteopontin expression in macrophages through interference with activator protein-1 signaling pathways. Circ Res 2005, 96: e59–e67.
- 50 Dai XY, Ou X, Hao XR, Cao DL, Tang YL, Hu YW, Li XX et al. Effect of T0901317 on hepatic proinflammatory gene expression in apoE−/− mice fed a high-fat/high-cholesterol diet. Inflammation 2007, 30: 105–117.
- 51 Yu PH. Deamination of methylamine and angiopathy; toxicity of formaldehyde, oxidative stress and relevance to protein glycoxidation in diabetes. J Neural Transm Suppl 1998, 52: 201–216.
- 52 Zhang YM, Chen XM, Wu D, Zhang XG, Lu Y, Shi SZ, Yin Z. Expression of tissue inhibitor of matrix metalloproteinase-1 in aging of transgenic mouse liver. Chin Med J 2006, 119: 504–509.
- 53 Didion SP, Ryan MJ, Didion LA, Fegan PE, Sigmund CD, Faraci FM. Increased superoxide and vascular dysfunction in CuZnSOD-deficient mice. Circ Res 2002, 91: 938–944.
- 54 Chen L, Pan DD, Zhou J, Jiang YZ. Protective effect of selenium-enriched Lactobacillus on CCl4-induced liver injury in mice and its possible mechanisms. World J Gastroenterol 2005, 11: 5795–5800.
- 55 Paigen B, Morrow A, Brandon C, Mitchell D, Holmes P. Variation in susceptibility to atherosclerosis among inbred strains of mice. Atherosclerosis 1985, 57: 65–73.
- 56 Paigen B, Ishida BY, Verstuyft J, Winters RB, Albee D. Athero sclerosis susceptibility differences among progenitors of recombi-nant inbred strains of mice. Arteriosclerosis 1990, 10: 316–323.
- 57 Yu PH, Deng YL. Endogenous formaldehyde as a potential factor of vulnerability of atherosclerosis: involvement of semicarbazide-sensitive amine oxidase-mediated methylamine turnover. Atherosclerosis 1998, 140: 357–363.
- 58 Yu PH, Wang M, Deng YL, Fan H, Shira-Bock L. Involvement of semicarbazide-sensitive amine oxidase-mediated deamination in atherogenesis in KKAy diabetic mice fed with high cholesterol diet. Diabetologia 2002, 45: 1255–1262.
